Aridis Pharmaceuticals to host a fireside chat with analysts

Aridis Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections has stated that it will host the "Fireside Chat Forum," with its five covering analysts on December 4th, 2020 at 11:00AM EST. This virtual event is intended to provide a 2021 preview and plans for the Company's lead clinical programs, COVID-19 mAb programs, and its novel antibody discovery platform technology.

"It is a pleasure to host this forum as it will offer efficient, yet comprehensive perspectives from leading Wall Street analysts on our programs and cutting-edge technology platform, especially in light of the current pandemic and on-going challenges facing the medical and science communities around emerging life-threatening infections," commented Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals.

The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with broad spectrum antibiotics.